Silverberg Bernstein Capital Management LLC Takes $70,000 Position in SOPHiA GENETICS SA (NASDAQ:SOPH)

Silverberg Bernstein Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 22,464 shares of the company’s stock, valued at approximately $70,000.

Other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares in the last quarter. Green Alpha Advisors LLC acquired a new position in SOPHiA GENETICS during the 3rd quarter valued at about $79,000. Finally, Federated Hermes Inc. increased its holdings in SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.40.

SOPHiA GENETICS Stock Up 0.6 %

SOPH opened at $3.40 on Wednesday. The company’s 50-day moving average price is $3.30 and its two-hundred day moving average price is $3.69. SOPHiA GENETICS SA has a twelve month low of $2.70 and a twelve month high of $7.37. The stock has a market cap of $222.28 million, a price-to-earnings ratio of -3.12 and a beta of 1.00. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The firm had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. During the same period last year, the company posted ($0.21) EPS. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.98 earnings per share for the current year.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.